Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

9 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis.

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

Ruxolitinib cream is effective for atopic dermatitis and prurigo nodularis, with low adverse event rates in long-term use. The cream reduces the need for other topical treatments and biologics in ...

Nemolizumab “is also the first and only biologic approved for atopic dermatitis and prurigo nodularis with 4-week dosing intervals from the start of treatment,” according to the statement.

Nemolizumab is also approved in the European Union and United States for both moderate-to-severe atopic dermatitis and prurigo nodularis. 5,6 Galderma’s leadership in Therapeutic Dermatology is ...

The approval covers prurigo nodularis in individuals aged 18 and older. It also includes atopic dermatitis, or eczema, in those aged 12 and over with a body weight of at least 30 kg. Nemolizumab ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...